BioNxt Solutions Inc

BioNxt secures global patents for its sublingual cladribine film, BNT23001, positioning the company to launch a fast‑dissolving MS/MG therapy and pursue worldwide licensing.

BioNxt’s melt‑in‑your‑mouth thin‑film boosts cladribin bioavailability by 40 % and is launching first‑in‑human trials for MS and rare neuromuscular disease.

BioNxt’s patented melt‑in‑mouth thin‑film platform offers a rapid, non‑invasive oral delivery for semaglutide, tackling 40 % of dysphagia patients and challenging injectable therapies.

BioNxt’s “Intention to Grant” from the EPO for a sublingual cladribine thin‑film could transform MS treatment and boost investor prospects.

BioNxt Solutions Inc. has made significant progress in its semaglutide oral dissolvable film program, completing proof-of-concept trials and reducing its debt by $225,010 through a settlement agreement.

BioNxt Solutions Inc. has received a formal notice from the European Patent Office to grant a patent for its innovative anticancer drug delivery technology, a key milestone for the company’s lead product BNT23001.